Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ashwagandha for Chemotherapy-Induced Cognitive Dysfunction
NCT04092647Phase 2Unknown
- Sponsor
- Sutter Health
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial (2 arms), sponsored by Sutter Health. Primary endpoint: Functional Assessment of Cancer Therapy-Cognitive Function Perceived Cognitive Impairment at 9 weeks. Status: unknown.
Beyond the preview
Go deeper on NCT04092647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04092647.